

RESEARCH ARTICLE

Evaluation of [Cys(ATTO 488)⁸]Dermorphin-NH₂ as a novel tool for the study of μ -opioid peptide receptors

Despina Giakomidi¹, Mark F. Bird¹, John McDonald¹, Erika Marzola², Remo Guerrini², Serena Chanoch¹, Nidhuna Sabu¹, Barbara Horley¹, Girolamo Calo³, David G. Lambert^{1*}

1 Department of Cardiovascular Sciences (Anaesthesia, Critical Care and Pain Management), University of Leicester, Leicester Royal Infirmary, Leicester, United Kingdom, **2** Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, Ferrara, Italy, **3** Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy

* dgl3@le.ac.uk



OPEN ACCESS

Citation: Giakomidi D, Bird MF, McDonald J, Marzola E, Guerrini R, Chanoch S, et al. (2021) Evaluation of [Cys(ATTO 488)⁸]Dermorphin-NH₂ as a novel tool for the study of μ -opioid peptide receptors. *PLoS ONE* 16(4): e0250011. <https://doi.org/10.1371/journal.pone.0250011>

Editor: Sadashiva S. Karnik, Cleveland Clinic Lerner Research Institute, UNITED STATES

Received: November 20, 2020

Accepted: March 29, 2021

Published: April 23, 2021

Copyright: © 2021 Giakomidi et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the manuscript and its [Supporting Information](#) files.

Funding: DG Lambert British Journal of Anaesthesia (major funding) NO grant number - small funder, funded in 2019 NO role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript DG Lambert British Heart Foundation (minor funding) www.bhf.org Grant number: PG/18/54/33896. NO role in the study design, data collection and

Abstract

The μ -opioid peptide (MOP) receptor is a member of the opioid receptor family and an important clinical target for analgesia. Measuring MOP receptor location and tracking its turnover traditionally used radiolabels or antibodies with attendant problems of utility of radiolabels in whole cells and poor antibody selectivity. To address these issues we have synthesized and characterised a novel ATTO488 based fluorescent Dermorphin analogue; [Cys(ATTO 488)⁸]Dermorphin-NH₂ (Derm_{ATTO488}). We initially assessed the binding profile of Derm_{ATTO488} in HEK cells expressing human MOP and CHO cells expressing human MOP, δ -opioid peptide (DOP), κ -opioid peptide (KOP) and Nociceptin/Orphanin FQ peptide (NOP) receptors using radioligand binding. Functional activity of the conjugated peptide was assessed by measuring (i) the ability of the ligand to engage G-protein by measuring the ability to stimulate GTP γ [³⁵S] binding and (ii) the ability to stimulate phosphorylation of ERK1/2. Receptor location was visualised using confocal scanning laser microscopy. Dermorphin and Derm_{ATTO488} bound to HEK_{MOP} (pK_i: 8.29 and 7.00; p<0.05), CHO_{MOP} (pK_i: 9.26 and 8.12; p<0.05) and CHO_{DOP} (pK_i: 7.03 and 7.16; p>0.05). Both ligands were inactive at KOP and NOP. Dermorphin and Derm_{ATTO488} stimulated the binding of GTP γ [³⁵S] with similar pEC₅₀ (7.84 and 7.62; p>0.05) and E_{max} (1.52 and 1.34fold p>0.05) values. Moreover, Dermorphin and Derm_{ATTO488} produced a monophasic stimulation of ERK1/2 phosphorylation peaking at 5mins (6.98 and 7.64-fold; p>0.05). Finally, in confocal microscopy Derm_{ATTO488} bound to recombinant MOP receptors on CHO and HEK cells in a concentration dependent manner that could be blocked by pre-incubation with unlabelled Dermorphin or Naloxone. Collectively, addition to ATTO488 to Dermorphin produced a ligand not dissimilar to Dermorphin; with ~10fold selectivity over DOP. This new ligand Derm_{ATTO488} retained functional activity and could be used to visualise MOP receptor location.

analysis, decision to publish, or preparation of the manuscript.

Competing interests: In the past DGL has held consultancy with Grunenthal (this does not alter our adherence to PLOS ONE policies on sharing data and materials) and is a non-executive director of the SME-CRO; Cellomatics. None of the remaining authors have conflicts to declare.

Introduction

Opioid receptors are members of the seven transmembrane-spanning G protein-coupled receptor (GPCR) superfamily. The μ (MOP), δ (DOP) and κ (KOP) receptors are classical or naloxone sensitive and the Nociceptin/Orphanin FQ (N/OFQ) receptor (NOP) is naloxone insensitive. Whilst all opioid receptors are capable of the production of analgesia, the main target in the clinic is the MOP receptor. MOP receptors couple to G_i/G_o G-proteins to enhance an outward potassium conductance to hyperpolarize, close voltage-sensitive calcium channels and inhibit adenylyl cyclase leading to the reduction of cAMP formation. In neurones this ultimately leads to reduced firing and neurotransmitter release [1–5].

The MOP receptor is widely distributed throughout the central nervous system and in neural and non-neural peripheral tissues [6]. Current methods to detect MOP receptor expression have several shortcomings. Use of radiolabels to study opioid receptors in native cells or tissue, where receptor densities are low is difficult due to the generally inadequate quantity of the sample that can be collected along with a relatively low specific activity of available radiolabels. Commercially available opioid receptor antibodies show poor selectivity and detection of mRNA does not necessarily indicate a functional protein [7–9]. There are a number of studies looking at turnover of tagged receptors. Typically these use receptors tagged with HA and FLAG but ultimately they require fixation and incubation with anti-HA or anti-FLAG antibodies [10, 11].

Dermorphin is a MOP receptor agonist isolated from the skin of the Amazon frog *Phyllomedusa sauvagei* in the early 1980s [12, 13]. Dermorphin binds to MOP with high affinity and an order of magnitude selectivity over DOP [14]. This relatively short (seven amino acids) peptide is easy to manipulate so we have used it as an acceptor for the fluorescent ATTO dye (488nm) to produce [Cys(ATTO 488)⁸]Dermorphin-NH₂ (Derm_{ATTO488}). The use of ATTO dyes leads to extended visualisation when compared to the more commonly used ALEXA dyes and linkage to bioactive peptides provides an increase in sensitivity when compared to use of antibodies or radioligand binding, particularly in low expression systems. Derm_{ATTO488} will have potential uses for tracking MOP receptors and when used in conjunction with other probes, for example N/OFQ_{ATTO594} [15] to examine opioid receptor interaction(s).

In this study we determine the binding properties of Dermorphin and Dermorphin_{ATTO488} along with functional activity in GTP γ [³⁵S] binding and ERK1/2 phosphorylation at recombinant human opioid receptors expressed in HEK and CHO cells. Importantly we use Derm_{ATTO488} to visualise MOP expression in live CHO and HEK cells using confocal microscopy.

Materials and methods

Materials

Dermorphin and Naloxone were purchased from Sigma-Aldrich Co. (Dorset, U.K.). Naltrindole and Dynorphin A were from Tocris (Abingdon, U.K.). Tritiated Diprenorphine ([³H]-DPN) and tritiated N/OFQ ([³H]-N/OFQ) was from Perkin Elmer. Tissue culture media and supplements were from Sigma-Aldrich and Gibco. All other materials and reagents were of the highest purity available.

Synthesis of [Cys(ATTO 488)⁸]Dermorphin-NH₂ (Derm_{ATTO488})

The conjugation of [Cys⁸]Dermorphin-NH₂ to ATTO 488 maleimide (purchased from ATTO-TEC GmbH Am Eichenhang 50 D-57076 Siegen Germany) was achieved using the classic thiol-Michael reaction. A solution of maleimide derivative fluorescent probe (1 mg, 1 equiv.) in CH₃CN (250 μ L) was added to a stirred solution of [Cys⁸]Dermorphin-NH₂ (1.1 equiv.) in 250 μ L of H₂O, followed by the addition of 25 μ L of NaHCO₃ 5%. The mixture was




Fig 1. Chemical structure of Dermorphin-ATTO488.

<https://doi.org/10.1371/journal.pone.0250011.g001>

stirred in the dark under a nitrogen atmosphere and at room temperature for 15 minutes. The reaction was monitored by analytical HPLC analysis and after completion, preparative HPLC purification of the reaction mixture. Quantitative yield is depicted in the supplement. S1 Fig in [S1 File](#) is an HPLC chromatogram and S2 Fig in [S1 File](#) is an MS spectra of the final product. Final product structure is shown in [Fig 1](#).

Cell culture

Human Embryonic Kidney (HEK) or Chinese Hamster Ovary (CHO) cells expressing recombinant human opioid receptors were cultured in MEM or HAM F-12 media respectively until >90% confluence. HEK_{hMOP} cells were prepared in house (plasmid coding for the MOP receptor was from <https://www.cdna.org/files/data/OPR0M10000.pdf>). CHO_{hMOP} and CHO_{hKOP} cells were provided by T Costa (Istituto Superiore di Sanita, Rome, Italy). CHO_{hDOP} were supplied by E Varga (University of Arizona, USA). CHO_{hNOP} were from GSK (Stevenage, Herts, UK). Media was supplemented with 10% foetal bovine serum, 100µg/ml penicillin, 100µg/ml streptomycin and 2.5µg/ml fungizone. Selection media used for stock cells expressing human recombinant classical opioid receptors (HEK_{hMOP}, CHO_{hMOP}, CHO_{hKOP} and CHO_{hDOP}) was supplemented with 200µg/ml geneticin (G418). The selection media for cells expressing human recombinant NOP (CHO_{hNOP}) also contained 200µg/ml hygromycin B. For the live-cell imaging experiments, cells were plated on ethanol-sterilised 25mm coverslips for 48h before use.

Membrane protein preparation

HEK_{hMOP}, CHO_{hMOP}, CHO_{hNOP}, CHO_{hKOP} and CHO_{hDOP} cells were harvested in harvest buffer consisting of 154mM NaCl, 10mM HEPES and 1.7mM EDTA, pH 7.4. Cells were homogenised (Ultra-Turrax T25 cell homogeniser) and membrane fragments were collected by centrifugation at 13,500rpm for 10min at 4 °C. Membranes were resuspended in fresh harvest buffer and the process was repeated once more. Finally, membranes were suspended in the required volume of assay buffer (0.5% BSA in 50mM Tris, pH 7.4). Protein concentration was determined using the Lowry method. For the GTPγ[³⁵S] binding assay, after harvesting the cells were suspended in homogenisation buffer consisting of 50mM Tris-HCl and 0.2mM EGTA, pH 7.4 and at the final step, membrane fragments were suspended in assay buffer consisting 50mM Tris, 0.2mM EGTA, 100mM NaCl and 1mM MgCl₂, pH 7.4.

Radioligand displacement assays

40µg of freshly prepared membrane protein was suspended in 0.5ml of buffer containing 50mM Tris, 0.5% BSA and ~0.8nM [³H]-Diprenorphine (DPN) (for HEK_{hMOP}, CHO_{hMOP},

CHO_{hKOP} and CHO_{hDOP}) or ~0.8nM [³H]-N/OFQ (for CHO_{hNOP}) and varying concentrations (1pM-1μM) of unlabelled Dermorphin or Derm_{ATTO488}. Non-specific binding was evaluated with 10μM naloxone for cells expressing the classical opioid receptors and 1μM N/OFQ for CHO_{hNOP}. Reference ligands were added as indicated in the results. After 1h incubation at room temperature reactions were terminated by vacuum filtration onto a PEI-soaked Whatman GF/B filter paper using a Brandel harvester [14, 16].

GTPγ[³⁵S] binding assay

40μg of freshly prepared membrane protein was suspended in 0.5ml of 50mM Tris-HCl buffer containing 0.2mM EGTA, 100mM NaCl, 1mM MgCl₂, 0.1% BSA, 0.15mM Bacitracin, 33mM GDP, ~240pM GTPγ[³⁵S] and varying concentrations (1pM-1μM) of unlabelled Dermorphin or Derm_{ATTO488}. Non-specific binding was determined with 10μM unlabelled GTPγS. Membranes were incubated for 1h at 30°C with gentle agitation. Reactions were terminated by vacuum filtration onto dry Whatman GF/B filter paper using a Brandel harvester [14, 16].

Western blotting–detection of ERK1/2 phosphorylation in HEK cells

HEK_{hMOP} cells were grown in 6-well plates coated with poly D lysine (0.1mg/ml) and serum starved for 24h. Cells were washed with Krebs buffer preheated to 37°C (118mM NaCl, 4.7mM KCl, 1.2mM KH₂PO₄, 1.2mM MgSO₄, 11.9mM Glucose, 10mM HEPES, 1.3mM CaCl₂, pH 7.4) for 30min. Dermorphin and Derm_{ATTO488} are subsequently added at a final concentration of 1μM and incubated for varying times (1min, 2.5min, 5min, 7.5min, 10min, 15min and 30min). Time zero was included as a control (no drug). Incubation was terminated by rinsing with ice cold PBS and the addition of lysis buffer (20mM Tris-HCl, 137mM NaCl, 2mM EDTA, glycerol, 10% Triton X-100, 0.054g b-Glycerophosphate, 0.018g sodium orthovanadate, 0.8μM pepstatin A, 500μM Leupeptin, 0.4mM benzamidine and 0.4mM PMSF). Reactions were centrifuged at 13,000rpm for 15min at 4°C then an equal volume of 2x sample buffer (Tris-HCl pH 6.8, 10% SDS, 38mM Glycine, 200mM DTT, bromophenol blue) was added and samples were heated to 95°C for 5min. 50μl of each sample, along with protein marker (biotinylated protein ladder #7727 Cell signalling technology) was loaded onto an 10% SDS-PAGE gel. Proteins were separated by electrophoresis at 150V for 1h in 1X Running buffer (Bio-Rad Laboratories). Proteins were transferred onto a nitrocellulose membrane (0.45μm, Thermo Fisher Scientific) in blotting buffer (39mM glycine, 48mM Tris-HCl, 0.037% SDS, 20% methanol) overnight. The membrane was stained with Ponceau S solution (1% w/v Ponceau in 1% Acetic Acid) for 3min on a rocker at room temperature. The membrane was then washed with dH₂O and TBST buffer (5M NaCl, 1M Tris-HCl pH 7.5, 0.05% Tween-20) and soaked in TBST-10% milk for 2h on a shaker. Monoclonal phospho-p44/42 MAPK (ERK1/2) antibody (dilution 1:6000, #4377S, Cell Signalling Technology) or Vinculin antibody (dilution 1:1200, #4650S, Cell Signalling Technology) were added to the membrane and incubated overnight at 4°C on a shaker. The anti-vinculin antibody was used as a control to ensure equal loading across the wells and proper transfer to the nitrocellulose membrane. Membrane was washed x5 with TBST and polyclonal anti-rabbit IgG (#A6154, Sigma Aldrich) or anti-biotin HRP (#7075, Cell Signalling Technology) was added. After 1h of incubation the membrane was washed, treated with Amersham ECL western blotting detection kit (RPN 2109, GE Healthcare) for 1min and bands were visualised using a BioRad Chemi-Doc MP Imager [14].

Live-cell imaging

Coverslip cultures of CHO or HEK cells were placed on a Harvard Peltier plate and perfused with Krebs buffer, pH 7.4 at 4°C (low temperature selected because Derm_{ATTO488} is an

agonist). Derm_{ATTO488} was injected onto coverslips at four different cumulative concentrations; 1nM, 10nM, 100nM or 1 μ M. Cells were incubated with the lowest Derm_{ATTO488} concentration for 3mins, washed with ice-cold Krebs buffer for 2min then imaged. After a further wash of 1mins in HEK cells or 3min in CHO cells (to produce z-stack) the next concentration was added and imaged as described. To define non-specific label binding cells were incubated with 25 μ M of unlabelled Dermorphin for 5min and then with 1 μ M of Derm_{ATTO488} added as above. Additional experiments were also performed using 15 μ M Naloxone to determine NSB. Images were taken using an oil immersed 60x objective in a Nikon C1Si microscope. Both HEK and CHO cells were imaged using the 488nm wavelength laser with a 20% power setting and a 7.15 gain-green channel. The laser and gain settings were maintained constant in both cell lines. Images were collected by the Nikon C1Si software. For the CHO cells only, due to the low signal observed, images were captured using the 'z-stack project'. All images were analysed using FIJI. Four random regions of interest (ROI) were selected and averaged for background fluorescence. For concentration fluorescence relationship analysis total corrected cell fluorescence was calculated according to the equation: Integrated density–(Area of selected cell X Mean fluorescence of background Readings) [15].

Data analysis

Data are expressed as mean \pm SEM for (n) individual experiments. In confocal experiments representative images are depicted from 5 independent experiments. All curve fitting was performed using Graphpad Prism 7. In radioligand experiments, ligand affinity (pK_i) was estimated from the concentration producing 50% displacement corrected for the competing concentration of label according to Cheng and Prusoff [17]. In GTP γ [³⁵S] assays, data are presented as a stimulation factor, that is the fold change in GTP γ [³⁵S] binding relative to the basal [14, 16]. The concentration of drug producing 50% of the maximum response (pEC₅₀) and the maximum response (E_{max}) are shown. Statistical analysis (as noted in text and Display legends) was via ANOVA with post-hoc correction and/or t-test as appropriate with P values <0.05 considered significant.

Results

We initially assessed binding affinity and selectivity before confirming ATTO conjugation retained biological activity in GTP γ [³⁵S] binding assay and ERK1/2 stimulation. Once this basic profile was confirmed live cell imaging was used to visualise cell surface binding.

[³H]-DPN / [³H]N/OFQ displacement to determine affinity and selectivity

In HEK_{hMOP} and CHO_{hMOP}, Dermorphin and Derm_{ATTO488} displaced the binding of [³H]-DPN in concentration dependent manner. In CHO_{hMOP} Derm_{ATTO488} displayed decreased binding affinity (pK_i 8.12) compared to Dermorphin (pK_i 9.26; p<0.05) Fig 2, Table 1. A reduction in affinity was also observed in HEK_{hMOP} (pK_i 7.00 and 8.29 for Derm_{ATTO488} and Dermorphin respectively; p<0.05) Fig 2, Table 1. In CHO_{hDOP} Dermorphin (pK_i 7.03) and Derm_{ATTO488} (pK_i 7.16) displaced the radioligand with similar affinity (p>0.05), Fig 2, Table 1. The pK_i values for Naltrindole, Dynorphin A and N/OFQ were previously published [14] so, in this study a single concentration (1 μ M) was used as a reference and this produced near full displacement. Both Dermorphin and Derm_{ATTO488} failed to displace [³H]-DPN in CHO_{hNOP} and CHO_{hKOP}, and [³H]N/OFQ in CHO_{hNOP} cells Fig 2, Table 1. Based on CHO cell data Dermorphin and Derm_{ATTO488} showed 172 and 9 fold selectivity for MOP over DOP receptors and were inactive at KOP and NOP.




Fig 2. [³H]-DPN displacement assay and GTPγ[³⁵S] activation assay. Displacement of [³H]-DPN by Dermorphin, Derm_{ATTO488}, N/OFQ, Dynorphin A and Naltrindole in (A) HEK_{hMOP}, (B) CHO_{hMOP}, (C) CHO_{hKOP}, (D) CHO_{hDOP} and (E) CHO_{hNOP}. Data are presented as mean (SEM) of n = 10 experiments for the HEK cells and n = 6 for CHO cell lines. pK_i values are shown in Table 1. Ligand stimulated GTPγ[³⁵S] binding by Dermorphin and Derm_{ATTO488} at CHO_{hMOP} (F). Data are presented as mean (±SEM) of n = 4 experiments. pEC₅₀ and E_{max} values are shown in Table 2.

<https://doi.org/10.1371/journal.pone.0250011.g002>

Table 1. Radioligand binding data.

	pK _i				
	HEK _{hMOP}	CHO _{hMOP}	CHO _{hDOP}	CHO _{hKOP}	CHO _{hNOP}
Dermorphin	8.29±0.18	9.26±0.13	7.03±0.17	<5	<5
Derm_{ATTO488}	7.00±0.10*	8.12±0.06*	7.16±0.23	<5	<5

Radioligand derived pK_i values for Dermorphin and Derm_{ATTO488} binding to MOP, DOP, KOP and NOP receptors as shown in Fig 2. Data are shown as mean±SEM of n = 10 for HEK_{MOP} and n = 6 for the CHO cells.

*p<0.05 (unpaired t-test) compared to Dermorphin.

<https://doi.org/10.1371/journal.pone.0250011.t001>

GTPγ[³⁵S] binding assay

In CHO_{hMOP} Dermorphin and Derm_{ATTO488} stimulated GTPγ[³⁵S] binding in a concentration dependent and saturable manner. The maximal response of Derm_{ATTO488} (E_{max} 1.34) was not significantly different (p>0.05) to that calculated for Dermorphin (E_{max} 1.52), Fig 2, Table 2. Derm_{ATTO488} and Dermorphin were equipotent (pEC₅₀ 7.84 compared to 7.62; p>0.05), Fig 2, Table 2.

Stimulation of ERK1/2 phosphorylation

A time-response curve in HEK_{MOP} showed that stimulation by 1μM of Derm_{ATTO488} led to a monophasic pattern of ERK1/2 phosphorylation peaking at 5min and returning towards baseline by 20mins. The peak activity was statistically significant compared to t = 0 and was 7.64 ±1.06 fold greater. Similar data were obtained for Dermorphin (6.98±1.22 fold). These maximum stimulation values were not significantly different from each other (p>0.05). The phosphorylation pattern for Dermorphin and Derm_{ATTO488} were essentially superimposable, Fig 3 (S3 Fig in S1 File shows the uncropped and unadjusted images of the blots).

Live-cell imaging

Four different concentrations of Derm_{ATTO488} (1nM, 10nM, 100nM and 1μM) were added to live HEK_{MOP} and CHO_{hMOP} cells and binding was measured using confocal microscopy and a 488nm laser, Figs 4 and 5. In all images nuclei are labelled with DAPI (blue) and the binding of Derm_{ATTO488} is shown in green. In both cell lines the binding was concentration dependent with the highest cell surface binding measured at the highest concentration used (1μM). Typical images are shown with average corrected total fluorescence for n = 5 independent experiments. Specificity of Derm_{ATTO488} (1μM) binding in single transfected lines (note; only MOP) was assessed by 5 min pre-incubation with an excess of unlabelled Dermorphin (25μM). As can be seen in Figs 4A and 5A there was demonstrable non-specific binding and this amounted to 16% and 19% in HEK_{hMOP} and CHO_{hMOP} respectively. Pre-incubation with

Table 2. GTPγ[³⁵S] binding in CHO_{hMOP} cell membranes.

	pEC ₅₀	E _{max}
Dermorphin	7.84±0.23	1.52±0.36
Derm_{ATTO488}	7.62±0.22	1.34±0.17

GTPγ[³⁵S] activation in CHO_{hMOP} cells by Dermorphin and Derm_{ATTO488}. Data show potency (pEC₅₀) and efficacy (E_{max}) derived from the data in Fig 2 and are presented as mean±SEM of n = 4 experiments. There were no statistically significant differences (p>0.05; unpaired t test).

<https://doi.org/10.1371/journal.pone.0250011.t002>




Fig 3. Activation of ERK1/2. (A) Representative blots for stimulation of phosphorylated ERK1/2 in HEK_{hMOP} by Dermorphin and Derm_{ATTO488}. The 117kDa band corresponds to the vinculin protein used as a housekeeper and the ~42-44kDa band to phosphorylated ERK1/2 (the uncropped and unadjusted images are provided in S3 Fig in S1 File). (B). Time-dependent ERK1/2 phosphorylation by Dermorphin and Derm_{ATTO488}. Data are presented as mean±SEM for n = 7. *p<0.05 compared to baseline according to ANOVA followed by Dunnett's test for multiple comparison.

<https://doi.org/10.1371/journal.pone.0250011.g003>

unlabelled Naloxone (15μM) also defined non-specific binding in both HEK_{hMOP} (16%) and CHO_{hMOP} (20%) (S4 and S5 Figs in S1 File). In untransfected wild type HEK and CHO cells Derm_{ATTO488} (1μM) bound at ultra-low levels, comparable to that defined by unlabelled Dermorphin and Naloxone (Figs 4A-inset and 5A-inset).

Discussion

In this study we have shown that conjugation of the MOP receptor agonist Dermorphin with the ATTO488 fluorophore produced a peptide ligand with slightly reduced binding affinity. Derm_{ATTO488} retained functional activity in GTPγ[³⁵S] binding and ERK1/2 phosphorylation with effects superimposable to those of the native peptide Dermorphin. The new ligand has ~10fold selectivity over DOP and is inactive at KOP and NOP opioid receptors. This new ligand could be effectively used to visualise MOP receptors in live cells. This is a significant




Fig 4. Concentration-dependent binding of Derm_{ATTO488} to MOP receptors expressed in HEK cells using confocal microscopy. Representative images of the binding of various concentrations (B: 1 μ M, C: 100nM, D: 10nM and E: 1nM). Nuclei are labelled (blue) with DAPI. Unlabelled (25 μ M) Dermorphin blocked the binding of 1 μ M Derm_{ATTO488} (16%) to the MOP receptors (A). Untransfected cells labelled 1 μ M Derm_{ATTO488} are depicted in A-inset. Image F shows mean corrected total cell fluorescence \pm SEM for $n = 5$ experiments and * $p < 0.05$ compared to NSB according to ANOVA followed by Dunnett's test for multiple comparison.

<https://doi.org/10.1371/journal.pone.0250011.g004>

advantage over the use of radiolabels with their attendant problems, the generally poor selectivity of commercially available antibodies and the need to employ tagged receptors.

Physical-chemical characterization of ATTO488 is extensive and resulted in fluorophore characteristics for use in localization-based super-resolution imaging [18]. Moreover, ATTO dyes are particularly useful as they exhibit prolonged fluorescence and reduced photobleaching properties [19]. For a synthetic perspective, the fast and high yield reactivity of the ATTO488 maleimide derivative in very mild conditions (room temperature, acetonitrile/water as a solvent) with thiol groups (like the-SH of Cys side chain) make this dye an excellent candidate for easy conjugation with peptide sequences.

The binding affinity of Dermorphin at MOP was 8.29 (HEK) and 9.26 (CHO) representing just under a 10-fold difference. The difference between CHO and HEK (higher affinity in HEK) is difficult to explain but could result from a larger proportion of receptors in the G-protein coupled state as this has higher affinity for agonists [20]. In a previous paper [14] using Dermorphin in CHO cells we reported pK_i values at MOP of 8.69 (4-fold weaker than the current data); pK_i at DOP was essentially identical and there was no activity at KOP or NOP. In this paper we reported GTP γ [³⁵S] binding and ERK1/2 phosphorylation [14]. A further potential explanation for the discrepancy in binding affinities could be differential coupling of MOP to additional protein(s) in CHO and HEK cells. Opioid receptors are known undergo extensive protein-protein interactions [21]. One such protein that has gained interest with respect to opioid receptor trafficking is Filamin A, a protein that couples membrane proteins to actin. However with respect to our data, Onoprishvili et al [22] showed that the binding of [³H] Diprenorphine and [³H]DAMGO were identical in M2 melanoma cells that do not express Filamin A and its subclone A7 transfected with this protein.




Fig 5. Concentration-dependent binding of Derm_{ATTO488} to the MOP receptors expressed in CHO cells using confocal microscopy. Representative images of the binding of various concentrations (B: 1 μM, C: 100 nM, D: 10 nM and E: 1 nM). Nuclei are labelled (blue) with DAPI. Unlabelled Dermorphin (25 μM) blocked the binding of 1 μM Derm_{ATTO488} (19%) to the MOP receptors (A). Untransfected cells labelled 1 μM Derm_{ATTO488} are depicted in A-inset. Image F shows mean corrected total cell fluorescence ± SEM for n = 5 experiments and *p < 0.05 compared to NSB according to ANOVA followed by Dunnett's test for multiple comparison.

<https://doi.org/10.1371/journal.pone.0250011.g005>

A key factor in using any receptor probe (fluorescent or radiolabelled) is to determine specificity of binding; or more specifically to define low non-specific binding (NSB). In these experiments we pre-incubated live cultures with the fluorophore parent; Dermorphin (an agonist) or the non-selective opioid receptor antagonist naloxone. In both cases Derm_{ATTO488} binding was displaced such that at 1 μM labelling concentrations only 16–20% of it was non-displaceable. NSB was at the higher end in CHO compared to HEK cellular background. To add a further layer of definition, untransfected HEK and CHO cells were incubated with 1 μM Derm_{ATTO488}; in the absence of MOP receptors, probe binding was low and comparable (raw fluorescence) to that observed in the traditional displacement based NSB definition.

We have also reported previously on the conjugation of ATTO594 (red) to the NOP ligand N/OFQ. Unlike conjugation of ATTO488 to Dermorphin this conjugation produced a fluorescent ligand with no loss of affinity. Moreover, N/OFQ_{ATTO594} displayed no activity at MOP, DOP or KOP and the ligand retained full biological activity in experiments to measure inhibition of cAMP formation and ERK1/2 phosphorylation. N/OFQ_{ATTO594} was used to visualise receptor location in recombinant and native (immune cells) NOP expression systems [15]. A further difference between the binding of Derm_{ATTO488} and N/OFQ_{ATTO594} relates to NSB. In the present study we report NSB for the Dermorphin ligand between 16 and 19%; for N/OFQ ligand the NSB was effectively undetectable in the conditions used.

There is extensive evidence for opioid dimers in both in vitro recombinant expression systems and in vivo [23–25]. Use of both N/OFQ_{ATTO594} (red) and Derm_{ATTO488} (green) in double expression systems where there is a possibility to use FRET to visualize NOP-MOP dimers will be an interesting further use of these new ligands. Studies with these new fluorescent ligands as agonists offer the possibility to examine receptor trafficking following activation of the receptor.

There have been other studies using opioid peptides conjugated to other fluorescent 'probes'. Gaudriault et al (1997) synthesized BODIPY derivatives of Dermorphin and the DOP peptide agonist Deltorphin-I. These probes were used in COS cells transfected with rat MOP and DOP receptors. The authors used these ligands in internalisation studies of live cells and showed that both were capable of visualising receptors and that receptor (probe) internalisation was time and temperature dependent [26]. A range of fluorescent peptide agonists including Dermorphin-Bodipy Texas Red and Dermorphin_{Alexa488} were synthesized by Arttamangkul et al. In radioligand binding studies using CHO cells expressing rat MOP and DOP the authors reported good MOP selectivity; no data are presented for KOP or NOP. Functional activity was confirmed electrophysiologically in rat locus ceruleus. Importantly at low temperature (4–8°C) binding measured by confocal microscopy in CHO cells was located to the membrane that internalized on warming (32–35°C). Interestingly, Alexa488 conjugated to the DOP antagonist TIPP bound but failed to internalize [27]. Further use of these Dermorphin-Bodipy Texas Red and Dermorphin_{Alexa488} probes in primary cultures of mouse locus ceruleus showed that desensitization is not dependent on receptor internalization [28].

There are a number of drawbacks to Derm_{ATTO488}. First, Dermorphin is an agonist and as such it will produce receptor activation; we have clearly shown that in this paper. In imaging experiments where cell surface receptor expression is critical activation will lead to Arrestin recruitment, we have shown this previously [14] and ultimately internalization. As such confocal experiments need to be performed at 4°C to limit this process. Whilst a clear disadvantage for studies examining internalisation, protocols to warm cells should enable the internalisation process to be tracked. The second major drawback (no issue in single recombinant expression systems) relates to selectivity of only ~10 fold over DOP noted above. In native tissues aimed at exploring MOP receptor expression, DOP receptors are also often co-expressed so careful use of label concentration is needed to allow discrimination or pre-blocking with highly selective DOP antagonists such as naltrindole.

In summary Derm_{ATTO488} represents a useful addition to the ligand toolkit to study opioid receptor expression, function and turnover.

Supporting information

S1 File.
(DOCX)

Author Contributions

Conceptualization: Remo Guerrini, Girolamo Calo, David G. Lambert.

Formal analysis: Despina Giakomidi, Mark F. Bird, John McDonald, Serena Chanoch, Nidhuna Sabu, Barbara Horley, David G. Lambert.

Funding acquisition: David G. Lambert.

Investigation: Despina Giakomidi, Mark F. Bird, John McDonald, Serena Chanoch, Nidhuna Sabu, Barbara Horley.

Methodology: Erika Marzola, Remo Guerrini, Girolamo Calo.

Resources: Erika Marzola, Remo Guerrini, Girolamo Calo.

Supervision: David G. Lambert.

Writing – original draft: Despina Giakomidi, Mark F. Bird, John McDonald, Erika Marzola, Remo Guerrini, Girolamo Calo, David G. Lambert.

Writing – review & editing: Despina Giakomidi, Mark F. Bird, John McDonald, Erika Marzola, Remo Guerrini, Serena Chanoch, Nidhuna Sabu, Barbara Horley, Girolamo Calo, David G. Lambert.

References

1. Stein C. Opioid Receptors. *Annu Rev Med.* 2016; 67:433–51. Epub 2015/09/04. <https://doi.org/10.1146/annurev-med-062613-093100> PMID: 26332001.
2. Pathan H, Williams J. Basic opioid pharmacology: an update. *Br J Pain.* 2012; 6(1):11–6. Epub 2012/02/01. <https://doi.org/10.1177/2049463712438493> PMID: 26516461; PubMed Central PMCID: PMC4590096.
3. Dietis N, Rowbotham DJ, Lambert DG. Opioid receptor subtypes: fact or artifact? *Br J Anaesth.* 2011; 107(1):8–18. Epub 2011/05/27. <https://doi.org/10.1093/bja/aer115> PMID: 21613279.
4. Lambert DG. The nociceptin/orphanin FQ receptor: a target with broad therapeutic potential. *Nat Rev Drug Discov.* 2008; 7(8):694–710. Epub 2008/08/02. <https://doi.org/10.1038/nrd2572> PMID: 18670432.
5. Azzam AAH, McDonald J, Lambert DG. Hot topics in opioid pharmacology: mixed and biased opioids. *Br J Anaesth.* 2019; 122(6):e136–e45. Epub 2019/04/24. <https://doi.org/10.1016/j.bja.2019.03.006> PMID: 31010646.
6. Peng J, Sarkar S, Chang SL. Opioid receptor expression in human brain and peripheral tissues using absolute quantitative real-time RT-PCR. *Drug Alcohol Depend.* 2012; 124(3):223–8. Epub 2012/02/24. <https://doi.org/10.1016/j.drugalcdep.2012.01.013> PMID: 22356890; PubMed Central PMCID: PMC3366045.
7. Guo Y, Xiao P, Lei S, Deng F, Xiao GG, Liu Y, et al. How is mRNA expression predictive for protein expression? A correlation study on human circulating monocytes. *Acta Biochim Biophys Sin (Shanghai).* 2008; 40(5):426–36. Epub 2008/05/10. <https://doi.org/10.1111/j.1745-7270.2008.00418.x> PMID: 18465028.
8. Niwa H, Rowbotham DJ, Lambert DG. Evaluation of primary opioid receptor antibodies for use in western blotting. *Br J Anaesth.* 2012; 108(3):530–2. Epub 2012/02/18. <https://doi.org/10.1093/bja/aes015> PMID: 22337965.
9. Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O'Donnell D, et al. Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. *Cell.* 2009; 137(6):1148–59. Epub 2009/06/16. <https://doi.org/10.1016/j.cell.2009.04.019> PMID: 19524516; PubMed Central PMCID: PMC3683597.
10. DeCaprio J, Kohl TO. Tandem Immunoaffinity Purification Using Anti-FLAG and Anti-HA Antibodies. *Cold Spring Harb Protoc.* 2019; 2019(2). Epub 2019/02/03. <https://doi.org/10.1101/pdb.prot098657> PMID: 30710027.
11. Li Y. Commonly used tag combinations for tandem affinity purification. *Biotechnol Appl Biochem.* 2010; 55(2):73–83. Epub 2010/02/17. <https://doi.org/10.1042/BA20090273> PMID: 20156193.
12. Hesselink JMK, Schatman ME. Rediscovery of old drugs: the forgotten case of dermorphin for postoperative pain and palliation. *J Pain Res.* 2018; 11:2991–5. Epub 2018/12/13. <https://doi.org/10.2147/JPR.S186082> PMID: 30538538; PubMed Central PMCID: PMC6260176.
13. Montecucchi PC, Henschen A. Amino acid composition and sequence analysis of sauvagine, a new active peptide from the skin of *Phyllomedusa sauvagei*. *Int J Pept Protein Res.* 1981; 18(2):113–20. Epub 1981/08/01. <https://doi.org/10.1111/j.1399-3011.1981.tb02047.x> PMID: 7309372.
14. Bird MF, Cerlesi MC, Brown M, Malfacini D, Vezi V, Molinari P, et al. Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). *PLoS One.* 2016; 11(6):e0156897. Epub 2016/06/09. <https://doi.org/10.1371/journal.pone.0156897> PMID: 27272042; PubMed Central PMCID: PMC4896453.
15. Bird MF, Guerrini R, Willets JM, Thompson JP, Calo G, Lambert DG. Nociceptin/Orphanin FQ (N/OFQ) conjugated to ATTO594: a novel fluorescent probe for the N/OFQ (NOP) receptor. *Br J Pharmacol.* 2018; 175(24):4496–506. Epub 2018/10/03. <https://doi.org/10.1111/bph.14504> PMID: 30276802; PubMed Central PMCID: PMC6255954.
16. Bird MF, Vardanyan RS, Hruba VJ, Calo G, Guerrini R, Salvadori S, et al. Development and characterisation of novel fentanyl-delta opioid receptor antagonist based bivalent ligands. *Br J Anaesth.* 2015; 114(4):646–56. Epub 2015/02/15. <https://doi.org/10.1093/bja/aeu454> PMID: 25680364; PubMed Central PMCID: PMC6223790.

17. Cheng Y, Prusoff WH. Relationship between the inhibition constant (K₁) and the concentration of inhibitor which causes 50 per cent inhibition (I₅₀) of an enzymatic reaction. *Biochem Pharmacol.* 1973; 22(23):3099–108. Epub 1973/12/01. [https://doi.org/10.1016/0006-2952\(73\)90196-2](https://doi.org/10.1016/0006-2952(73)90196-2) PMID: 4202581.
18. Dempsey GT, Vaughan JC, Chen KH, Bates M, Zhuang X. Evaluation of fluorophores for optimal performance in localization-based super-resolution imaging. *Nat Methods.* 2011; 8(12):1027–36. Epub 2011/11/08. <https://doi.org/10.1038/nmeth.1768> PMID: 22056676; PubMed Central PMCID: PMC3272503.
19. Sobek JA, C. Schlapbach R. Analyzing Properties of Fluorescent Dyes Used for Labeling DNA in Microarray Experiments BioFiles2011. Available from: <https://www.sigmaaldrich.com/technical-documents/articles/biofiles/analyzing-properties.html>.
20. Strange PG. Agonist binding, agonist affinity and agonist efficacy at G protein-coupled receptors. *Br J Pharmacol.* 2008; 153(7):1353–63. Epub 2008/01/29. <https://doi.org/10.1038/sj.bjp.0707672> PMID: 18223670; PubMed Central PMCID: PMC2437915.
21. Georgoussi Z, Georganta EM, Milligan G. The other side of opioid receptor signalling: regulation by protein-protein interaction. *Curr Drug Targets.* 2012; 13(1):80–102. Epub 2011/07/23. <https://doi.org/10.2174/138945012798868470> PMID: 21777181.
22. Onoprishvili I, Andria ML, Kramer HK, Ancevska-Taneva N, Hiller JM, Simon EJ. Interaction between the mu opioid receptor and filamin A is involved in receptor regulation and trafficking. *Mol Pharmacol.* 2003; 64(5):1092–100. Epub 2003/10/24. <https://doi.org/10.1124/mol.64.5.1092> PMID: 14573758.
23. Massotte D. In vivo opioid receptor heteromerization: where do we stand? *Br J Pharmacol.* 2015; 172(2):420–34. Epub 2014/03/29. <https://doi.org/10.1111/bph.12702> PMID: 24666391; PubMed Central PMCID: PMC4292957.
24. Evans RM, You H, Hameed S, Altier C, Mezghrani A, Bourinet E, et al. Heterodimerization of ORL1 and opioid receptors and its consequences for N-type calcium channel regulation. *J Biol Chem.* 2010; 285(2):1032–40. Epub 2009/11/06. <https://doi.org/10.1074/jbc.M109.040634> PMID: 19887453; PubMed Central PMCID: PMC2801230.
25. Gomes I, Ayoub MA, Fujita W, Jaeger WC, Pflieger KD, Devi LA. G Protein-Coupled Receptor Heteromers. *Annu Rev Pharmacol Toxicol.* 2016; 56:403–25. Epub 2015/10/31. <https://doi.org/10.1146/annurev-pharmtox-011613-135952> PMID: 26514203; PubMed Central PMCID: PMC5147582.
26. Gaudriault G, Nouel D, Dal Farra C, Beaudet A, Vincent JP. Receptor-induced internalization of selective peptidic mu and delta opioid ligands. *J Biol Chem.* 1997; 272(5):2880–8. Epub 1997/01/31. <https://doi.org/10.1074/jbc.272.5.2880> PMID: 9006932.
27. Arttamangkul S, Alvarez-Maubecin V, Thomas G, Williams JT, Grandy DK. Binding and internalization of fluorescent opioid peptide conjugates in living cells. *Mol Pharmacol.* 2000; 58(6):1570–80. Epub 2000/11/28. <https://doi.org/10.1124/mol.58.6.1570> PMID: 11093798.
28. Arttamangkul S, Torrecilla M, Kobayashi K, Okano H, Williams JT. Separation of mu-opioid receptor desensitization and internalization: endogenous receptors in primary neuronal cultures. *J Neurosci.* 2006; 26(15):4118–25. Epub 2006/04/14. <https://doi.org/10.1523/JNEUROSCI.0303-06.2006> PMID: 16611829; PubMed Central PMCID: PMC6673897.